SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 25,037 shares of the company’s stock, valued at approximately $4,394,000. Astrazeneca accounts for about 0.2% of SBI Okasan Asset Management Co.Ltd.’s holdings, making the stock its 16th largest holding.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Kestra Investment Management LLC boosted its holdings in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after buying an additional 63 shares during the period. Luken Investment Analytics LLC boosted its holdings in Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after purchasing an additional 64 shares during the period. Addison Advisors LLC lifted its holdings in shares of Astrazeneca by 3.9% during the 4th quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock worth $305,000 after acquiring an additional 65 shares during the period. Western Wealth Management LLC lifted its holdings in shares of Astrazeneca by 2.5% during the 4th quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock worth $507,000 after acquiring an additional 71 shares during the period. Finally, Soltis Investment Advisors LLC lifted its holdings in shares of Astrazeneca by 2.2% during the 4th quarter. Soltis Investment Advisors LLC now owns 3,470 shares of the company’s stock worth $609,000 after acquiring an additional 76 shares during the period. Institutional investors own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
AZN has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Thursday, May 14th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.
Astrazeneca Price Performance
AZN stock opened at $185.66 on Friday. The company has a 50 day simple moving average of $191.34 and a 200 day simple moving average of $183.64. The stock has a market cap of $287.94 billion, a price-to-earnings ratio of 27.88, a P/E/G ratio of 1.48 and a beta of 0.26. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.
Astrazeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts anticipate that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
